Charles River Laboratories (CRL)
Provider of research models, nonclinical drug-development services, and manufacturing quality-control testing.
$287.20
vs last close+8.19 (+2.94%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 43 days
EPS estimate
$2.96
Revenue estimate
$958.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$2.66$2.34$3.12$2.43$2.39$2.06$3.02Pending
Estimate$2.50$2.06$2.50$2.32$2.33$1.96$2.74$2.96
Surprise+6.4%+13.6%+24.8%+4.7%+2.6%+5.1%+10.2%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.00B$984.2M$1.03B$1.00B$994.2M$995.8M$1.00BPending
Estimate$948.2M$958.8M$968.9M$987.2M$987.0M$977.5M$977.2M$958.3M
Surprise+5.7%+2.6%+6.5%+1.8%+0.7%+1.9%+2.8%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $3.64 | — | — |
| Sep 2028 | $3.57 | — | — |
| Jun 2028 | $3.40 | — | — |
| Mar 2028 | $3.03 | — | — |
| Dec 2027 | $3.32 | — | — |
| Sep 2027 | $3.19 | — | — |
| Jun 2027 | $3.21 | — | — |
| Mar 2027 | $2.76 | — | — |
| Dec 2026 | $3.32 | — | — |
| Nov 2026 | $2.96 | — | — |
| Aug 2026 | $2.74 | $3.02 | +10.2% |
| May 2026 | $1.96 | $2.06 | +5.1% |
| Feb 2026 | $2.33 | $2.39 | +2.6% |
| Nov 2025 | $2.32 | $2.43 | +4.7% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $3.64 | — | — | $1.03B | — | — | — |
| Sep 2028 | $3.57 | — | — | $1.06B | — | — | — |
| Jun 2028 | $3.40 | — | — | $1.05B | — | — | — |
| Mar 2028 | $3.03 | — | — | $1.01B | — | — | — |
| Dec 2027 | $3.32 | — | — | $985.3M | — | — | — |
| Sep 2027 | $3.19 | — | — | $982.4M | — | — | — |
| Jun 2027 | $3.21 | — | — | $1.01B | — | — | — |
| Mar 2027 | $2.76 | — | — | $976.3M | — | — | — |
| Dec 2026 | $3.32 | — | — | $952.0M | — | — | — |
| Nov 4, 2026 | $2.96 | — | — | $958.3M | — | — | — |
| Aug 5, 2026 | $2.74 | $3.02 | +10.2% | $977.2M | $1.00B | +2.8% | +11.4% |
| May 7, 2026 | $1.96 | $2.06 | +5.1% | $977.5M | $995.8M | +1.9% | −0.0% |
| Feb 18, 2026 | $2.33 | $2.39 | +2.6% | $987.0M | $994.2M | +0.7% | −0.3% |
| Nov 5, 2025 | $2.32 | $2.43 | +4.7% | $987.2M | $1.00B | +1.8% | −5.7% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 19, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 14, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 11, 2023 | |||||||
| Feb 22, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 16, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 17, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 11, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 13, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 10, 2018 | |||||||
| Feb 13, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 10, 2017 | |||||||
| Feb 14, 2017 | |||||||
| Nov 2, 2016 | |||||||
| Aug 3, 2016 | |||||||
| May 4, 2016 | |||||||
| Feb 10, 2016 | |||||||
| Nov 4, 2015 | |||||||
| Jul 30, 2015 |